We also found the RFSPem benefit for patients with cutaneous melanoma who were pretreated with IFN-α (median RFSPem 14.4 months vs. 3.2 months, Figure S3B), but the difference was not significant. The gene discussed is IFNA1; the disease is cutaneous melanoma.